{"groups":[{"description":"Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG000","title":"Group 1 - Recurrent or Refractory Hepatoblastoma"},{"description":"Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG001","title":"Group 2 - Recurrent or Refractory Synovial Sarcoma"},{"description":"Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG002","title":"Group 3 - Recurrent or Refractory Rhabdomyosarcoma"},{"description":"Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG003","title":"Grp 4-Recurrent or Refractory Adrenocortical Carcinoma"},{"description":"Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG004","title":"Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor"},{"description":"Group 6 - Recurrent or Refractory Neuroblastoma -meta-iodobenzylguanidine (MIBG) Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG005","title":"Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease"},{"description":"Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG006","title":"Grp 7-Neuroblastoma With Measurable Disease"},{"description":"Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG007","title":"Group 8 - Recurrent Osteosarcoma"},{"description":"Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG008","title":"Group 9 - Recurrent or Refractory Wilms Tumor"},{"description":"Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG009","title":"Group 10 - Recurrent or Refractory Retinoblastoma"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"17"},{"groupId":"FG006","numSubjects":"8"},{"groupId":"FG007","numSubjects":"9"},{"groupId":"FG008","numSubjects":"7"},{"groupId":"FG009","numSubjects":"0"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"Ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"21"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"14"},{"groupId":"FG005","numSubjects":"20"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"9"},{"groupId":"FG009","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"20"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"14"},{"groupId":"FG005","numSubjects":"19"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"9"},{"groupId":"FG009","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"No patients were enrolled in Group 10, recurrent or refractory retinoblastoma."}